International Journal of Pharmaceutics 2015-06-20

An in-vitro-in-vivo model for the transdermal delivery of cholecalciferol for the purposes of rodent management.

J Davies, A Ingham

Index: Int. J. Pharm. 487 , 101-9, (2015)

Full Text: HTML

Abstract

The natural selection of anticoagulant resistant rats has resulted in a need for an alternative to anticoagulant rodenticides which differs in both active ingredient and in the method of dosing. Cholecalciferol toxicity to rodents using the dermal route is demonstrated using a variety of penetration enhancing formulations in two in-vitro models and finally in-vivo. A 1 ml dose of 50/50 (v/v) DMSO/ethanol containing 15% (v/v) PEG 200 and 20% (w/v) cholecalciferol was judged as 'sufficiently effective' in line with the European Union's Biocidal Products Regulation (No. 528/2012) during in-vivo studies. This dose was found to cause 100% mortality in a rat population in 64.4h (± 22h).Copyright © 2015 The Authors. Published by Elsevier B.V. All rights reserved.